Impact of Duration of Dose Interruption on the Efficacy of Lenvatinib (LEN) in A Phase III Study in Patients (pts) With Radioiodine Refractory Differentiated Thyroid Cancer (RR-DTC)-MedSci.cn

Impact of Duration of Dose Interruption on the Efficacy of Lenvatinib (LEN) in A Phase III Study in Patients (pts) With Radioiodine Refractory Differentiated Thyroid Cancer (RR-DTC)

Tahara, M; Brose, M; Wirth, L; Suzuki, T; Fujino, K; Batty, N; Dutcus, C; Young, L; Gianoukakis, A

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017; 13 ( ): 139

科室
- - 订阅+
  - 更多科室
工具
服务